arrow
R

Ryan J. Sullivan

Harvard Medical School
H指数:90
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

双特异性双T细胞激动剂invikafusp alfa在实体瘤中的研究:第1/2期START-001试验

2026-10-230
PRE
An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

在GNAQ/GNA11突变型黑色素瘤中具有Gq/11抑制剂载荷的抗PMEL抗体−药物偶联物:一项1期临床试验

2026-07-130
OA
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma

针对BCL2家族蛋白的个性化靶向策略可克服BRAF-MEK抑制剂在黑色素瘤模型中的获得性耐药

2026-06-260
OAAI
Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance

多模态血液蛋白质组学分析揭示了免疫治疗耐药机制的见解

2026-06-240
OA
Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases

整合多模态管理与分子分型在BRAF V600E阳性黑色素瘤伴脑转移患者中的应用

2026-03-260
OAAI
Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma
2025-11-010
PRE
NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY

早期临床经验:肿瘤浸润淋巴细胞(TIL)疗法治疗患者中,放射性疗法管理黑色素瘤脑转移的应用

2025-11-010
OAAI
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients

联合局部疗法可延长tebentafusp在转移性眼葡萄膜黑色素瘤患者中的临床获益

2025-10-010
OAAI
B NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY

B 新的临床经验:使用放射治疗管理接受肿瘤浸润淋巴细胞(TIL)疗法患者的黑色素瘤脑转移

2025-10-010
OAAI
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma

成熟和迁移的树突状细胞促进免疫浸润以及对转移性黑素瘤中抗PD-1检查点阻断的应答

2025-09-010
OAAI
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants

通过靶向CD38克服人类肿瘤移植组织对免疫治疗的抵抗

2025-06-270
OAAI
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Monson, K.R.; Ferguson, R.; Handzlik, J.E.; Morales, L.; Xiong, J.; Chat, V.; Dagayev, S.; Khodadadi-Jamayran, A.; Simpson, D.; Kazlow, E.; 等. 继承的线粒体遗传学作为预测黑色素瘤免疫检查点抑制疗效的指标。Nat. Med. 2025, 31, 2385–2396. [Google Scholar] [CrossRef]

2025-06-050
OAAI
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors

评估免疫检查点抑制剂治疗后慢性皮肤免疫相关不良事件的特征

2025-05-010
PRE
Cutaneous melanoma

皮肤黑色素瘤

2025-04-030
PRE